Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R P Baum

Showing results (121-130 of 136) with videos related to

Pageof 14
Sort By:
Nuclear Medicine Communications|November 14, 1997
Pharmacokinetics and radiation dosimetry of 99Tcm-labelled monoclonal antibody B43.13 in ovarian cancer patientsS A McQuarrie, R P Baum, A Niesen, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 8, 2015
Gene transcript analysis blood values correlate with ⁶⁸Ga-DOTA-somatostatin analog (SSA) PET/CT imaging in neuroendocrine tumors and can define disease statusL Bodei, M Kidd, I M Modlin, et al.
European Journal of Nuclear Medicine|January 1, 1990
Multi-centre immunoscintigraphic study using indium-111-labelled CEA-specific and/or 19-9 monoclonal antibody F(ab')2 fragmentsA Chetanneau, R P Baum, P A Lehur, et al.
Clinical & Experimental Metastasis|August 8, 2014
The search for the primary tumor in metastasized gastroenteropancreatic neuroendocrine neoplasmD Kaemmerer, N Posorski, F von Eggeling, et al.
European Journal of Cancer (Oxford, England : 1990)|March 5, 2016
Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow-upDieter Hörsch, Samer Ezziddin, Alexander Haug, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 8, 2013
The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumoursL Bodei, J Mueller-Brand, R P Baum, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|August 25, 2012
Peptide receptor radionuclide therapy for neuroendocrine tumors in Germany: first results of a multi-institutional cancer registryDieter Hörsch, Samer Ezziddin, Alexander Haug, et al.
Nuklearmedizin. Nuclear Medicine|February 17, 2015
[Peptide receptor radionuclide therapy for patients with somatostatin receptor expressing tumours. German Guideline (S1)]T D Poeppel, C Boy, A Bockisch, et al.
Nuklearmedizin. Nuclear Medicine|March 15, 2018
[Somatostatin receptor PET/CT (SSTR-PET/CT)]C Boy, T Poeppel, J Kotzerke, et al.
Der Pathologe|May 20, 2015
[Neuroendocrine neoplasms of the breast]M Anlauf, M Neumann, S Bomberg, et al.
Pageof 14

Showing results (121-130 of 136) with videos related to

Sort By:
Pageof 14
Nuclear Medicine Communications|November 14, 1997
Pharmacokinetics and radiation dosimetry of 99Tcm-labelled monoclonal antibody B43.13 in ovarian cancer patientsS A McQuarrie, R P Baum, A Niesen, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 8, 2015
Gene transcript analysis blood values correlate with ⁶⁸Ga-DOTA-somatostatin analog (SSA) PET/CT imaging in neuroendocrine tumors and can define disease statusL Bodei, M Kidd, I M Modlin, et al.
European Journal of Nuclear Medicine|January 1, 1990
Multi-centre immunoscintigraphic study using indium-111-labelled CEA-specific and/or 19-9 monoclonal antibody F(ab')2 fragmentsA Chetanneau, R P Baum, P A Lehur, et al.
Clinical & Experimental Metastasis|August 8, 2014
The search for the primary tumor in metastasized gastroenteropancreatic neuroendocrine neoplasmD Kaemmerer, N Posorski, F von Eggeling, et al.
European Journal of Cancer (Oxford, England : 1990)|March 5, 2016
Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow-upDieter Hörsch, Samer Ezziddin, Alexander Haug, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 8, 2013
The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumoursL Bodei, J Mueller-Brand, R P Baum, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|August 25, 2012
Peptide receptor radionuclide therapy for neuroendocrine tumors in Germany: first results of a multi-institutional cancer registryDieter Hörsch, Samer Ezziddin, Alexander Haug, et al.
Nuklearmedizin. Nuclear Medicine|February 17, 2015
[Peptide receptor radionuclide therapy for patients with somatostatin receptor expressing tumours. German Guideline (S1)]T D Poeppel, C Boy, A Bockisch, et al.
Nuklearmedizin. Nuclear Medicine|March 15, 2018
[Somatostatin receptor PET/CT (SSTR-PET/CT)]C Boy, T Poeppel, J Kotzerke, et al.
Der Pathologe|May 20, 2015
[Neuroendocrine neoplasms of the breast]M Anlauf, M Neumann, S Bomberg, et al.
Pageof 14